AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03916393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bitrex solution
Description: Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
Study NCT00707330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week
Study NCT00707330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week
Study NCT02316015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infatrini® or Infatrini Peptisorb®
Study NCT02849496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study NCT01565746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
Study NCT01565746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00850499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
Study NCT00850499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
Study NCT00850499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: rituximab 375mg/m2 on Day 1 of every 35-day cycle
Study NCT00850499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02849496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT02849496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01864135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI (Magnetom Verio 3T, Erlangen, Germany)
Study NCT01864135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)
Study NCT01486680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass
Description: An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
Study NCT01486680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve gastrectomy
Description: Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg orally twice daily
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
Study NCT02614794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral dose twice daily
Study NCT00552305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Study NCT02018250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB4 DMS
Description: Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
Study NCT00195845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Study NCT00195845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT04332809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline-gentamicin irrigation
Description: Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
Study NCT04332809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline irrigation
Description: Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
Study NCT01915628 — intervention group
Intervention type: DEVICE
Intervention: BioMatrix Flex
Description: Percutaneous coronary intervention
Study NCT02018250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
Study NCT03701789 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Effect of Baricitinib on vBMD measured by HR-pQCT
Study NCT04977544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vert
Description: On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
Study NCT04977544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
Study NCT04977544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
Study NCT03865342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Coach DPP
Description: Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
Study NCT03501277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-4833 BL
Description: SYR-322-4833 BL FDC tablets.
Study NCT02944747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & paper based calendar
Description: The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
Study NCT02944747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & SMS system
Description: The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
Study NCT02944747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & smart-phone application
Description: The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
Study NCT04438135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated open application test
Description: parallel application of two different types of lotion with and without aluminium.
Study NCT04438135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repeated open application test
Description: parallel application of two different types of lotion with and without aluminium.
Study NCT01558687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug (including placebo)
Description: Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide.
Study NCT01558687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
Study NCT00693186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBVaxPRO® 5 µg / 0.5 mL
Description: 5 µg / 0.5 mL
Study NCT00693186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B® 10 µg / 0.5 mL
Description: 10 µg
Study NCT00968734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colecalciferol
Description: 50.000UI single oral dose
Study NCT02016807 — intervention group
Intervention type: DEVICE
Intervention: ProThelial
Description: August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
Study NCT02849496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT00675142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: Changing the time span between ovulation induction and IUI during fertility treatment.
Study NCT04715295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Tablets
Description: Doxycycline 200 mg daily for 7 days
Study NCT04715295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15Mg Tab
Description: Rivaroxaban 15 mg tablets daily from day 1 to day 10
Study NCT04715295 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
Study NCT02702245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Thylakoids 5 g
Description: 75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
Study NCT02702245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Thylakoids 10 g
Description: 75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
Study NCT02702245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: 75 g pure glucose.
Study NCT04449029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
Study NCT04449029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Study NCT02285244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin acetate
Description: Given PO
Study NCT02285244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02285244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00180453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery drug eluting stent placement
Description: Coronary artery drug eluting stent placement
Study NCT00180453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery stent placement
Description: Coronary artery stent placement
Study NCT04251936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
Study NCT04251936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation group program
Description: Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
Study NCT04251936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation group program
Description: Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
Study NCT02171208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Reference form
Description: single dose 240 mg
Study NCT02171208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate - Test form
Description: single dose 240 mg
Study NCT05192785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry Group
Description: The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it.
Study NCT02046187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
Study NCT02046187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients receive standard dose (60Gy/30 fractions) external beam radiation
Study NCT02046187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
Study NCT02825537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
Study NCT02825537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No use of compression stocking
Description: No use of compression stocking
Study NCT00202995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: 20 mg s.c. daily
Study NCT00202995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron
Description: 250 mg every other day
Study NCT00202995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Description: 44 ug 3 times a week
Study NCT00565760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: Capsules
Study NCT00565760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT01272856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 125 mg pre-filled syringe for sub-q injection weekly.
Study NCT01049672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Titrated to a maximum dose of 50mg in 24 hours subcutaneously
Study NCT01049672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamorphine
Description: Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
Study NCT02818062 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cytokines dosage in Aqueous humor
Description: Specify details not covered in associated Arm Description.
Study NCT02369250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, is a statin group of drug.
Study NCT02369250 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin
Description: AUTOLOGUS PLATELET GROWTH FACTOR